Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis

Fineline Cube Jan 15, 2026
Company Deals

Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases

Fineline Cube Jan 15, 2026
Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Fineline Cube Jan 15, 2026
Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Fineline Cube Jan 15, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Policy / Regulatory

Shanghai Health Commission Implements Strict Guidelines to Curb Medical Sector Misconduct

Fineline Cube Apr 9, 2024

The Shanghai Municipal Health Commission has issued the “Implementation Rules for the Nine Guidelines for...

Company Drug

GSK’s ViiV Healthcare Expands Dovato Indication to Include Adolescents with HIV-1 Infection

Fineline Cube Apr 9, 2024

GlaxoSmithKline’s (GSK; NYSE: GSK) ViiV Healthcare has received an indication extension from the US Food...

Company Drug

Johnson & Johnson’s Xarelto Demonstrates Reduced Bleeding Risk in Atrial Fibrillation Patients Post-PCI

Fineline Cube Apr 9, 2024

Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from a Phase...

Company Drug

Clover Bio’s SCB-1019 Vaccine Candidate Shows Promising Results in Phase I Trial

Fineline Cube Apr 9, 2024

Clover Biopharmaceuticals (HKG: 2197), a leading biotechnology company based in China, has announced robust preliminary...

Company Drug

Bristol Myers Squibb Reports Positive Long-Term Data for KarXT in Schizophrenia Trial

Fineline Cube Apr 9, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced preliminary long-term data from a...

Company Drug

Beijing Aosaikang Pharmaceuticals Achieves Clinical Milestone for c-MET Inhibitor ASKC202

Fineline Cube Apr 9, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced the presentation of promising data from...

Company Deals Drug Medical Device

Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab

Fineline Cube Apr 9, 2024

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent...

Company Drug

CStone Pharmaceuticals Submits New Drug Application for Gavreto in China, Eyes Local Manufacturing

Fineline Cube Apr 9, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has submitted a market...

Company Deals

Medicxi-Led Investment Boosts D3 Bio’s Development of Best- in-Class Oncology Therapies

Fineline Cube Apr 9, 2024

UK life sciences investment firm Medicxi has taken the lead in a $62 million Series...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures IND Approvals for Two Drug Candidates from China’s NMPA

Fineline Cube Apr 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received Investigational New Drug (IND) approvals from...

Company Drug

Abbisko Therapeutics Achieves Milestone in Global Phase III Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor

Fineline Cube Apr 9, 2024

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the completion of subject...

Company Drug

Luye Pharma’s Subsidiary Boan Biotech Completes Phase III Trial for Eylea Biosimilar BA9101

Fineline Cube Apr 9, 2024

Shandong Boan Biotechnology Co., Ltd., a subsidiary of China-based Luye Pharma Group (HKG: 2186), has...

Company Medical Device

Adicon Launches GuardantOMNI Test to Advance Tumor Therapy Development in China

Fineline Cube Apr 8, 2024

Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the...

Company Deals

Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates

Fineline Cube Apr 8, 2024

German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life...

Company Deals

Johnson & Johnson Acquires Shockwave Medical in a Landmark Deal to Expand Cardiovascular Portfolio

Fineline Cube Apr 8, 2024

Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced the acquisition of Shockwave Medical...

Policy / Regulatory

China’s CDE Issues Guidelines for Semaglutide Biosimilar Clinical Trials with Weight Management Focus

Fineline Cube Apr 8, 2024

The Center for Drug Evaluation (CDE) in China has released a new set of Guidelines...

Company Drug

AstraZeneca’s Imfinzi Achieves Positive Results in Late-Stage Trial for Small Cell Lung Cancer

Fineline Cube Apr 8, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its...

Company Drug

Novartis’s Leqvio Showcases Real-World Efficacy in Managing Cholesterol in ASCVD Patients

Fineline Cube Apr 8, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small...

Policy / Regulatory R&D

Beijing Unveils Comprehensive Measures to Boost Innovative Medicine Development

Fineline Cube Apr 8, 2024

The Beijing Municipal Medical Insurance Bureau, in conjunction with eight other bureaus, has announced a...

Policy / Regulatory

Guangzhou and Zhuhai Unveil Measures to Stimulate Biopharmaceutical Industry Growth

Fineline Cube Apr 8, 2024

In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and...

Posts pagination

1 … 321 322 323 … 610

Recent updates

  • Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis
  • Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases
  • NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation
  • J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
  • Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis

Company Deals

Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases

Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.